Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
301-315 of 4654 results
Daiichi Sankyo to close Japanese research subsidiary
Daiichi Sankyo has decided to further reorganize its R&D structure by closing its Japanese research subsidiary, Asubio Pharma in Kobe by the end of March 2018 after reviewing its global R&D structure to increase R&D productivity.
Drug Research > Drug Discovery & Development > News
FDA plans to not to hold advisory committee meeting for Portola’s betrixaban NDA
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) is not planning to hold an Advisory Committee meeting for Portola Pharmaceuticals' New Drug Application (NDA) for betrixaban.
Drug Research > Drug Discovery & Development > News
Prexton Therapeutics raises €29m in Series B Financing
Prexton Therapeutics has closed a €29m Series B round led by Forbion Capital Partners and Seroba Life Sciences.
Drug Research > Drug Discovery & Development > News
Acticor Biotech raises €1.5m in new funding
Acticor Biotech, a bio-pharmaceutical company focused on the treatment of acute ischemic stroke, has raised €1,5m from CapDecisif Management.
Drug Research > Drug Discovery & Development > News
Chondrial Therapeutics secures $22.6m in Series A financing
Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.
Drug Research > Drug Discovery & Development > News
Portola Pharma assigns AndexXa royalties to HealthCare Royalty Partners
Portola Pharmaceuticals has sold the royalty rights to AndexXa (andexanet alfa) to HealthCare Royalty Partners (HCR) for up to $150m.
Drug Research > Drug Discovery & Development > News
Tarveda Therapeutics completes $30m Series D equity financing
Tarveda Therapeutics has raised $30m in series D financing to advance pentarin miniaturized drug conjugates.
Drug Research > Drug Discovery & Development > News
Ferring, Enteris to develop oral formulation of peptide-based injectable therapeutic
Ferring Pharmaceuticals and Enteris BioPharma have signed a license agreement to develop an oral formulation of a peptide-based injectable therapeutic.
Drug Research > Drug Discovery & Development > News
Biscayne Neurotherapeutics raises $3m for antiepileptic compound
Biscayne Pharmaceuticals has raised financing for its new spin-out, Biscayne Neurotherapeutics, which was recently established to develop its biopharmaceutical assets for the treatment of neurological disorders.
Drug Research > Drug Discovery & Development > News
Celgene to buy biotechnology company Delinia
Celgene has agreed to acquire Delinia, a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases.
Drug Research > Drug Discovery & Development > News
Johnson & Johnson to buy Actelion for $30bn
By PBR Staff Writer
US healthcare giant Johnson & Johnson (J&J) has agreed to acquire Swiss biopharmaceutical firm Actelion for $30bn.
Drug Research > Drug Discovery & Development > News
Connect secures $25m financing to advance immune modulators clinical development
Connect Biopharmaceuticals has completed a $20m Series A financing to advance clinical development of novel immune modulators.
Drug Research > Drug Discovery & Development > News
Discuva secures Innovate UK grant for new antibiotics development
Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.
Drug Research > Drug Discovery & Development > News
Cue Biopharma raises $26M in funding
Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.
Drug Research > Drug Discovery & Development > News
ELC Group partners with PSR Group for advanced drug development
Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.
Drug Research > Drug Discovery & Development > News
301-315 of 4654 results